NCT00562341

Brief Summary

The proposed prospective study aims to determine whether interpretation of PSA levels in morbidly obese men require correction due to the obesity itself. If PSA levels are found to rise after weight loss, interpretation of PSA levels in morbidly obese men may be improved by upward correction of the PSA level. A 'correction factor' may be proposed for the interpretation of PSA levels in obese men, toward the clinical decision regarding indication for prostate biopsy.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Nov 2007

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

November 20, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 22, 2007

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2009

Completed
Last Updated

August 23, 2018

Status Verified

August 1, 2018

Enrollment Period

2.2 years

First QC Date

November 20, 2007

Last Update Submit

August 21, 2018

Conditions

Keywords

obesitypsaprostate cancer

Outcome Measures

Primary Outcomes (1)

  • Prostate-Specific Antigen (PSA) value

    The PSA serum test measures the level of PSA in a man's blood. The results are usually reported as nanograms of PSA per milliliter (ng/mL) of blood.

    18 months

Secondary Outcomes (4)

  • Effect of Lapband-induced weight loss on quality of life

    18 months

  • Effect of Lapband-induced weight loss on sexual function

    18 months

  • Effect of Lapband-induced weight loss on prostate size and associated urinary symptoms

    18 months

  • Receiver Operating Curve (ROC) analysis to evaluate PSA cancer detection performance

    18 months

Study Arms (1)

bariatric surgery

description of enrollees

Other: Bariatric Surgery

Interventions

one time lapb-band gastric bypass surgery

bariatric surgery

Eligibility Criteria

Age20 Years - 60 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Patients asked to enroll will be obese men who are undergoing bariatric surgery, lap-band surgery, at Maimonides Medical Center.

You may qualify if:

  • obese men undergoing lap-band surgery

You may not qualify if:

  • prior diagnosis of prostate cancer
  • prior prostate surgery
  • use of 5-alpha reductase inhibitors
  • history of prostatitis
  • recurrent Urinary Tract Infection (UTI).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maimonides Medical Center

Brooklyn, New York, 11219, United States

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

blood samples

MeSH Terms

Conditions

ObesityProstatic NeoplasmsSalivary Gland Adenoma, Pleomorphic

Interventions

Bariatric Surgery

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsGenital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

BariatricsObesity ManagementTherapeuticsSurgical Procedures, Operative

Study Officials

  • Jason Wynberg, MD

    MMC

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
18 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 20, 2007

First Posted

November 22, 2007

Study Start

November 1, 2007

Primary Completion

December 31, 2009

Study Completion

December 31, 2009

Last Updated

August 23, 2018

Record last verified: 2018-08

Locations